ClinicalTrials.gg
Status unknownNCT03447301Updated Feb 27, 2018

The Effect of Daily Consumption of Extra Virgin Olive Oil on Blood Glucose Among Diabetic Patients

An interventional study of Extra virgin olive oil (30mL daily) in Type 2 Diabetes Mellitus, sponsored by Sulaiman AlRajhi Colleges. Status unknown at 1 site in Saudi Arabia. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-02-27.

Sponsored by Sulaiman AlRajhi Colleges · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
20 Years to 60 Years
Sex
All
01

Study summary

Saudi Arabia has the highest prevalence (24%) of type 2 diabetes mellitus (T2DM) among the modern nation states in the world. In addition, majority of Saudi diabetic patient do not have their blood glucose controlled. Data suggests that diet, rich in olive oil and nuts, significantly reduces fasting plasma glucose and HbA1c (glycated hemoglobin). Olive oil has been associated with weight reduction as well as improvements in lipid profile (increase in high density (HDL) and decrease in low-density lipoprotein (LDL)). No randomized controlled trial has specifically examined the effect of olive oil as a supplement on blood glucose among diabetics. The study objective is to test the effect of daily consumption (30 mL) of extra-virgin olive oil (EVOO) on HbA1c among patients with type 2 diabetes.

Read the detailed description

Problem: Saudi Arabia has the highest prevalence (24%) of type 2 diabetes mellitus (T2DM) among the modern nation states in the world. In addition, majority of Saudi diabetic patient do not have their blood glucose controlled.

Significance: Data suggests that diet, rich in olive oil and nuts, significantly reduces fasting plasma glucose and HbA1c (glycated hemoglobin). Olive oil has been associated with weight reduction as well as improvements in lipid profile (increase in high density (HDL) and decrease in low-density lipoprotein (LDL)). No randomized controlled trial has specifically examined the effect of olive oil as a supplement on blood glucose among diabetics.

Objectives: To test the effect of daily consumption (30 mL) of extra-virgin olive oil (EVOO) on HbA1c among patients with type 2 diabetes.

Methods: The study design will be an open-label randomized controlled trial with 2 groups (EVOO versus no oil). The study will include 420 patients and each patient will be followed for 3 months. Group difference in HbA1c will be compared at 3 months to determine the effect of EVOO.

Implications: Dietary supplementation of EVOO could aid Saudi diabetic patients in keeping blood glucose levels controlled.

02

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Saudi Arabia, Extra Virgin Olive Oil, Blood Glucose
03

In context

Diabetes Mellitus, Type 2

10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.

This study's planned enrollment of 400 is above the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Sulaiman AlRajhi Colleges is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosed with Type 2 diabetes within 10 years of enrollment
  • baseline > 7%,
  • willing to supplement the diet with oil
  • able to read and write

Exclusion criteria

Exclusion Criteria:

  • type 1 diabetes mellitus
  • have gall-bladder or liver diseases or malabsorption or Crohn's disease
  • have advanced heart disease
  • have an aversion or allergy to olive oil
  • already using olive oil daily as a dietary supplement
  • morbidly obese ( >40 kg/m2)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Extra virgin olive oil

    Extra virgin olive oil (30mL) daily

    Dietary Supplement: Extra virgin olive oil (30mL daily)

  • No intervention
    Control

    No consumption of extra virgin olive oil

Interventions

  • Dietary supplementExtra virgin olive oil (30mL daily)

    Intervention arm will take 30 mL of Extra virgin olive oil daily.

06

What researchers measure

Primary outcomes

  1. HbA1c (glycated hemoglobin)

    Time frame: 3-month follow-up

Secondary outcomes

  1. Fasting Plasma Glucose

    Time frame: 3-month follow-up

  2. Lipid Profile

    High-density lipoprotein (HDL), Low-density lipoprotein (LDL), HDL/LDL ratio, triglycerides (TG), Cholesterol

    Time frame: 3-month follow-up

  3. Weight

    Time frame: 3-month follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2018; primary completion for Aug 2018, 6 months later.

Of 2,066 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 6 months is below that.

Counting every sponsor, half of 2,243 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2018
First posted
Feb 27, 2018
StartEst.
Feb 25, 2018
Primary completionEst.
Aug 25, 2018
CompletionEst.
Dec 25, 2018
Last update
Feb 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03447301
Lead sponsor
Sulaiman AlRajhi Colleges
Collaborators
Qassim University, Ministry of Health, Saudi Arabia
Responsible party
Sponsor
First posted
Feb 27, 2018
Start date
Feb 25, 2018 (estimated)
Primary completion
Aug 25, 2018 (estimated)
Completion
Dec 25, 2018 (estimated)
Last update
Feb 27, 2018

Study contacts

Nazmus Saquib, PhD
Contact
a.saquib@sr.edu.sa
966 0533445899
Juliann Saquib, PhD
Contact
juliannsaquib@qumed.edu.sa
966 507136832
Nazmus Saquib, PhD
principal investigator · Sulaiman Al-Rajhi Colleges

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion